GLPG 5301
Alternative Names: GLPG-5301Latest Information Update: 04 Mar 2026
At a glance
- Originator Galapagos NV
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 24 Feb 2026 Galapagos terminates a phase I/II PAPILIO-1 trial for Multiple myeloma (Second-line therapy or greater) in Europe (Parenteral) as the company decides to wind down cell therapy development
- 21 Oct 2025 Galapagos NV plans to wind down cell therapy therapeutics as per business strategy
- 30 Oct 2024 Galapagos resumes enrolment in the phase I/II PAPILIO-1 trial for Multiple myeloma in Europe